Evidence map›Paper›PMID 41272924›Full record

ArticleArchiv der Pharmazie2025

Identification of Novel β-Lactam Derivatives as Proteasome Inhibitors for Antitumor Therapy.

Yu Cao, Gaoya Xu, Lixin Gao, Jingjing Sun, Lu Zhang, Qiao Tong, Limin Kong, Jiankang Zhang, Yubo Zhou, Li Liao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archiv der Pharmazie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yu CaoDepartment of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou, China.ORCID https://orcid.org/0009-0009-8931-4316
Gaoya XuState Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Lixin GaoState Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Jingjing SunDepartment of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou, China.
Lu ZhangDepartment of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou, China.
Qiao TongDepartment of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou, China.
Limin KongDepartment of Clinical Pharmacy, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Jiankang ZhangKey Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, China.
Yubo ZhouState Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Li LiaoDepartment of Pharmacy, Hangzhou Children's Hospital, Hangzhou, China.
Liping FuDepartment of Pharmacy, Shaoxing TCM Hospital Affiliated to Zhejiang Chinese Medical University, Shaoxing, China.
Jianjun XiDepartment of Pharmaceutical Preparation, Hangzhou Xixi Hospital, Hangzhou, China.ORCID https://orcid.org/0000-0003-4306-7136

Funding

This study was funded by the Construction Fund of Key Medical Disciplines of Hangzhou (2025HZZD13), the Zhejiang Provincial Natural Science Foundation of China (LTGY24B020001), the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2024KY210), the Zhejiang Province Traditional Chinese Medicine Science and Technology Project (2024ZL760 and 2024ZR177), the Medical Health Science and Technology General Project of Hangzhou Health Commission (A20230089 and A20230210), the Hospital Pharmacy Research Project of Zhejiang Pharmaceutical Association (No. 2019ZYY14) and the Clinical Scientific Project from Zhejiang Medical Association (2020ZYC-A109).
6 · The paper itself

Abstract

A series of dipeptidic proteasome inhibitors with β-lactam as the C-terminus was designed and synthesized. Biochemical evaluations of their effects on chymotrypsin-like (CT-L) activity revealed that some of them had inhibitory activity against the proteasome, with IC

Indexed as

Antineoplastic Agentsbeta-LactamsProteasome InhibitorsApoptosisCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular StructureProteasome Endopeptidase ComplexStructure-Activity RelationshipAntineoplastic Agentsbeta-LactamsProteasome Endopeptidase ComplexProteasome Inhibitorsantitumorproteasome inhibitorsstructure–activity relationshipsβ‐lactam

Identifiers

PMID41272924
PMCPMC12638514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.